Mr. Sylvain Boucher reports

ERGORESEARCH ANNOUNCES THE MONETIZATION TRANSACTION OF THE SLEEP APNEA TECHNOLOGY

Ergoresearch Ltd.'s wholly owned subsidiary Victhom Laboratory Inc. received a net royalty payment of $590,000 representing its share of the net proceeds generated by the monetization transaction of the sleep apnea technology completed by its German partner Otto Bock Healthcare. Under the terms of the royalty agreement between Victhom Laboratory and Otto Bock Healthcare, the sleep apnea technology could also generate additional royalty payments on future net sales if the sleep apnea technology is commercialized.

M. Sylvain Boucher, president and chief executive officer of Ergoresearch, states: "The technology, based on the neurostimulation platform developed by Victhom, is an implantable medical device for recording and stimulation of peripheral nerves for treatment of obstructive sleep apnea. It can detect sleep apnea and deliver therapy only when necessary. According to the National Sleep foundation, sleep apnea affects 18 million Americans. Sleep apnea has severe consequences on quality of life, being strongly associated with high blood pressure, heart failure, diabetes and stroke. The Gold Standard Therapy, CPAP (1), is often rejected by patients. (2) Even though the transaction is under a confidentiality agreement, this monetization event represents a strong validation of the potential of the sleep apnea technology."

(1) CPAP: continuous positive air pressure

(2) Weaver and Grunstein, 2008

We seek Safe Harbor.